Condition: Multiple Myeloma in Relapse · Multiple Myeloma, Refractory · Acute Lymphoblastic Leukemia, in Relapse · Sponsor: Zhejiang University
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
This description comes directly from the study's public registry record.
He Huang, PhD · 86-13605714822 · hehuangyu@126.com
Yongxian Hu, PhD · 86-15957162012 · huyongxian2000@aliyun.com
Always discuss trial participation with your own doctor first.
| The First Hospital of Zhejiang Medical Colleage Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04603872